Autres langues Scandion Oncology A/S

Actions

SCOL

DK0061031895

Temps Différé Nasdaq Stockholm Autres places de cotation 09:45:36 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,288 ^SEK	-0,69 %		-26,53 %	-92,79 %

22/05	Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
22/05	Scandion Oncology A/S présente ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE	25/06
Scandion announces change of Certified Adviser to Vator Securities	03/06
SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE	31/05
Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension	27/05
Scandion Oncology – Interim Report Q1 2024	22/05
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	22/05
Invitation to Scandion Oncology webcast and conference call May 22, 2024	16/05
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101	13/05
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101	13/05
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors	06/05
Scandion Oncology to Host R&D Update May 15	03/05
Scandion Oncology – Notice convening the Annual General Meeting	19/04
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival	21/03
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	21/03
Scandion Oncology - Annual Report 2023	15/03
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial	07/03
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	07/03
Scandion Oncology Q4 2023 - Striving towards randomised controlled data	01/03
Scandion Oncology – Q4 & yearend report 2023	28/02
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Scandion Oncology A/S

Actions

SCOL

DK0061031895

Autres langues

Filtres